Journal of the National Cancer Institute
-
J. Natl. Cancer Inst. · Jan 2016
The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
The late cardiac effect of adjuvant trastuzumab and its potential interaction with anthracycline have not been well-studied on a population level. ⋯ Adjuvant trastuzumab was associated with increased risk of new incidence of HF in breast cancer survivors during the period of adjuvant treatment but not thereafter. Routine intensive monitoring may not be necessary after completing adjuvant therapy.
-
J. Natl. Cancer Inst. · Jan 2016
Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.
Randomized clinical trials have shown the 9-valent human papillomavirus (HPV) vaccine to be highly effective against types 31/33/45/52/58 compared with the 4-valent. Evidence on the added health and economic benefit of the 9-valent is required for policy decisions. We compare population-level effectiveness and cost-effectiveness of 9- and 4-valent HPV vaccination in the United States. ⋯ Switching to a 9-valent gender-neutral HPV vaccination program is likely to be cost-saving if the additional cost/dose of the 9-valent is less than $13. Giving females the 9-valent vaccine provides the majority of benefits of a gender-neutral strategy.
-
J. Natl. Cancer Inst. · Jan 2016
Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma.
This study aimed to establish an effective prognostic nomogram with or without plasma Epstein-Barr virus DNA (EBV DNA) for nondisseminated nasopharyngeal carcinoma (NPC). ⋯ The proposed nomogram with or without plasma EBV DNA resulted in more accurate prognostic prediction for NPC patients.